Behavioral strategies during incubation influence nest and female survival of Wild Turkeys

Females must balance physiological and behavioral demands of producing offspring with associated expenditures, such as resource acquisition and predator avoidance. Nest success is an important parameter underlying avian population dynamics. Galliforms are particularly susceptible to low nest success due to exposure of ground nests to multiple predator guilds, lengthy incubation periods, and substantive reliance on crypsis for survival. Hence, it is plausible that nesting individuals prioritize productivity and survival differently, resulting in a gradient of reproductive strategies. Fine-scale movement patterns during incubation are not well documented in ground-nesting birds, and the influence of reproductive movements on survival is largely unknown. Using GPS data collected from female wild turkeys (n = 278) across the southeastern United States, we evaluated the influence of incubation recess behaviors on trade-offs between nest and female survival. We quantified daily recess behaviors including recess duration, recess frequency, total distance traveled, and incubation range size for each nest attempt as well as covariates for nest concealment, nest attempt, and nest age. Of 374 nests, 91 (24%) hatched and 39 (14%) females were depredated during incubation. Average nest survival during the incubation period was 0.19, whereas average female survival was 0.78. On average, females took 1.6 daily unique recesses (SD = 1.2), spent 2.1 hr off the nest each day (SD = 1.8), and traveled 357.6 m during recesses (SD = 396.6). Average nest concealment was 92.5 cm (SD = 47). We found that females who took longer recess bouts had higher individual survival, but had increased nest loss. Females who recessed more frequently had lower individual survival. Our findings suggest behavioral decisions made during incubation represent life-history trade-offs between predation risk and reproductive success on an unpredictable landscape

Long-term eclipse timing of white dwarf binaries: an observational hint of a magnetic mechanism at work

We present a long-term programme for timing the eclipses of white dwarfs in close binaries to measure apparent and/or real variations in their orbital periods. Our programme includes 67 close binaries, both detached and semi-detached and with M-dwarfs, K-dwarfs, brown dwarfs or white dwarfs secondaries. In total, we have observed more than 650 white dwarf eclipses. We use this sample to search for orbital period variations and aim to identify the underlying cause of these variations. We find that the probability of observing orbital period variations increases significantly with the observational baseline. In particular, all binaries with baselines exceeding 10 yr, with secondaries of spectral type K2 – M5.5, show variations in the eclipse arrival times that in most cases amount to several minutes. In addition, among those with baselines shorter than 10 yr, binaries with late spectral type (>M6), brown dwarf or white dwarf secondaries appear to show no orbital period variations. This is in agreement with the so-called Applegate mechanism, which proposes that magnetic cycles in the secondary stars can drive variability in the binary orbits. We also present new eclipse times of NN Ser, which are still compatible with the previously published circumbinary planetary system model, although only with the addition of a quadratic term to the ephemeris. Finally, we conclude that we are limited by the relatively short observational baseline for many of the binaries in the eclipse timing programme, and therefore cannot yet draw robust conclusions about the cause of orbital period variations in evolved, white dwarf binaries

Biological Earth observation with animal sensors

Space-based tracking technology using low-cost miniature tags is now delivering data on fine-scale animal movement at near-global scale. Linked with remotely sensed environmental data, this offers a biological lens on habitat integrity and connectivity for conservation and human health; a global network of animal sentinels of environmen-tal change

MoveApps: a serverless no-code analysis platform for animal tracking data

Abstract Background Bio-logging and animal tracking datasets continuously grow in volume and complexity, documenting animal behaviour and ecology in unprecedented extent and detail, but greatly increasing the challenge of extracting knowledge from the data obtained. A large variety of analysis methods are being developed, many of which in effect are inaccessible to potential users, because they remain unpublished, depend on proprietary software or require significant coding skills. Results We developed MoveApps, an open analysis platform for animal tracking data, to make sophisticated analytical tools accessible to a global community of movement ecologists and wildlife managers. As part of the Movebank ecosystem, MoveApps allows users to design and share workflows composed of analysis modules (Apps) that access and analyse tracking data. Users browse Apps, build workflows, customise parameters, execute analyses and access results through an intuitive web-based interface. Apps, coded in R or other programming languages, have been developed by the MoveApps team and can be contributed by anyone developing analysis code. They become available to all user of the platform. To allow long-term and cross-system reproducibility, Apps have public source code and are compiled and run in Docker containers that form the basis of a serverless cloud computing system. To support reproducible science and help contributors document and benefit from their efforts, workflows of Apps can be shared, published and archived with DOIs in the Movebank Data Repository. The platform was beta launched in spring 2021 and currently contains 49 Apps that are used by 316 registered users. We illustrate its use through two workflows that (1) provide a daily report on active tag deployments and (2) segment and map migratory movements. Conclusions The MoveApps platform is meant to empower the community to supply, exchange and use analysis code in an intuitive environment that allows fast and traceable results and feedback. By bringing together analytical experts developing movement analysis methods and code with those in need of tools to explore, answer questions and inform decisions based on data they collect, we intend to increase the pace of knowledge generation and integration to match the huge growth rate in bio-logging data acquisition

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

PurposePembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB study evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in patients with LA HNSCC.Patients and methodsEligible patients included those with oral cavity (excluding lip), oropharyngeal, hypopharyngeal, or laryngeal stage III to IVB HNSCC (according to American Joint Committee on Cancer, 7th edition, staging system) eligible for cisplatin-based, standard-dose (70 Gy) chemoradiotherapy. Pembrolizumab was administered concurrently with and after chemoradiotherapy with weekly cisplatin. Safety was the primary end point and was determined by incidence of chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) imaging or with pathologic confirmation at 100 days postradiotherapy completion. Key secondary end points included overall (OS) and progression-free survival (PFS).ResultsThe study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n = 25) from November 2015 to October 2018. Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients completed the full planned treatment dose (70 Gy) of radiotherapy without any delays ≥ 5 days; 88.1% of patients completed the goal cisplatin dose of ≥ 200 mg/m2. EOT CR rates were 85.3% and 78.3% for those with HPV-positive and -negative HNSCC, respectively.ConclusionPembrolizumab in combination with weekly cisplatin-based chemoradiotherapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC. Early efficacy data support further investigation of this approach